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Addiction to Medicines
Findings from the DH commissioned reports from 
the NAC and NTA.
Introduction
• Evidence presented  to the APPG inquiry, raised 
concerns:
1. Availability prescription and sale (POM/OTC 
medicines)
2. Possible mis-prescribing of tranquilisers by GPs –
Longer term prescriptions
3. Possible shortage of services to help people addicted 
to legal medicine
Introduction
• The Department of Health commissioned two reports;
1. A literature review – published evidence on the extent of the 
problem and how best to respond to dependence (National 
Addictions Centre)
2. A consultative review – Investigate prescribing patterns and the 
services and support available to people who develop 
problems.
• Peer reviewed and launched via a written ministerial statement to 
Parliament on 11 May 2011
Key Questions:
1. Surveillance -What is the extent of the problem?
2. Access - What is the availability of services to 
support people?
3. Treatment Delivery - How effective are these 
services in supporting people to recovery from their 
dependency?
1. Prescribing Trends
1. Hypnotics and Anxiolytics
1. Opioid Analgesics
1. Prescribing Trends
• There has been a substantial decrease in the dispensing of 
benzodiazepines.
• Benzodiazepines to used treatment insomnia.
• Benzodiazepines to treat anxiety and opioid pain-killers
• OTC sales of Codeine containing compounds
• 659,980,416 in 2006 to 689,415,210 in 2008. 
1. Geographic differences
Opioid Analgesics Benzodiazepines
• Greater variation at Partnership level
Interesting but...
• Trend data tells us something about the use of these 
medicines
• Levels of prescribing can identify areas where there 
might need to be further focus (particularly at a practise 
level.)
• But: 
– Higher levels of prescribing do not necessarily mean 
that these drugs are not being used appropriately.
1. Long–term prescribing?
• Longer-term prescribing increases the likelihood of dependency.
• Does the prevalence of long-term prescribing give us an 
indication of the prevalence of dependency?
• “There are an estimated 1.5M people on long-term prescriptions 
for tranquillisers” (Panorama -The Tranquilliser Trap – BBC, 2001)
• Dependency is not inevitable 
• There are conditions where long-term prescribing is 
advised.
1. Long–term prescribing?
• RDGP data looked an available sample of a large national cohort 
also prescribed opiate substitution therapy
• Median length of prescription = 29 days
• 35.3% longer than 8 weeks
• 50% in subset with concurrent OST.
• 80% of local partnerships reported local preventative activity
• Local audit information suggests that dose enhancement is
possible via early pick ups.
1. Key Questions (Surveillance )
1. How can we be better informed about the overall extent of the issue 
and what drives changes over time (such as the increased use of 
opioid painkillers)?
2. What information do local areas require to support them to better 
understanding need?
3. What should be done to improve public understanding of treatment
for anxiety, insomnia and pain?
4. What actions should be taken to prevent problems from occurring in 
the first place?
2.Treatment Data
• NDTMS – Useful indicator of illegal drug trends due to 
the readily availability treatment.
• Collects data on an extensive list of  POM + OTC.
• Access to treatment  is a good indication of 
dependency.
• How many people are reported on NDTMS? 
• Does anyone report this in the absence of illegal drug use? 
2.Treatment Data
• In 2009/10 there were 32,510 people reporting 
POM/OTC (16% of treatment population)
• 11% of these (3,735) POM/OTC only
• Most local areas provide treatment
• POM/OTC + illegal drug use – 147 Parterships
• POM/OTC only – 120 Partnerships
2. Geographic distribution
• Variation at sub-national level with North East having the    
highest proportion of POM/OTC in treatment
2. Geographic Distribution
2. Demographics
• The vast majority are white.
• POM/OTC + illegal drug user very similar to general drug   
treatment population in terms of age and gender.
• POM/OTC only are almost twice as likely to be female and over 
40. 
2. Trends in treatment
2. Trends in treatment
2. Key questions (Access)
5. How can we ensure that the availability of support 
reflects the local need and changes over time?
6. How can we make people more aware of the services 
that are available to support them?
3. Service models and 
treatment effectiveness
3. Service models and 
Treatment effectiveness
• Good engagement in treatment 
• 6 months +
• Those reporting problems with just POM/OTC higher rate of 
successful completions. 
• Outcomes for POM/OTC + illegal drug group are not as 
positive
3. Response from the local 
partnerships.
• Most local areas provide some treatment for people who develop 
problems in relation to medicines.
• Service models:
– Dedicated POM/OTC services.
– Via local drug treatment services.
– GPs – often supported by local services.
• Local issues:
– Difficult to quantify unmet need
– Services provided by GP’s not always reported to NDTMS.
– How to define outcome measures for this client group
3. Response from the local 
services.
• All services recruited to the study were able to report to NDTMS
• Dedicated POM/OTC services had a higher proportion of POM/OTC only 
clients but also met the needs of those with problems in relation to illegal 
drugs
• Service models:
– Wide range of interventions provided in a variety of settings.
– Waiting times less than three weeks
– Higher proportion of planned exits for POM/OTC only
• Local issues:
– Access to psychological therapies
– Links to mental health and pain services undeveloped
– Protocols for dose reduction for different client groups not always clear
3. Key questions (Service Delivery)
• What training and guidance  is needed to support 
clinicians and how can this best impact on practice?
• How should we measure the outcomes of treatment for 
this group?
• How can we improve the coordination of care for the 
group across all health services (i.e. GP services, 
Increasing Access to Psychological Therapy (IAPT), 
mental health and pain services?
Question review
7.     What training or guidance is needed to support clinicians and how can this best impact on 
their practice?
8.     How should we measure the outcomes of treatment for this group?
9.     How can we improve the coordination of care for patients across all health services (i.e. 
GP services, Talking therapies, mental health and pain services.)
5. How can we ensure that the availability of support reflects the local need and changes 
over time?
6. How can we make people more aware of the availability of services?
1. How can we be better informed about the overall extent of the issue and what drives 
changes over time?
2. What information do local areas require to support them to better understanding need
3. What should be done to improve public understanding of treatments for anxiety, insomnia 
and pain?
4. What actions should be taken to prevent problems in relation to addiction to medicines 
from occurring in the first place?
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www.nta.nhs.uk/addiction-to-medicine.aspx www.kcl.ac.uk/iop/depts/addictions/research/drugs/b
enzodiazepinesz-drugsandcodeineproducts.aspx
